Scisparc is a biotechnology business based in the US. Scisparc shares (SPRC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.25 – an increase of 8.2% over the previous week. Scisparc employs 3 staff and has a trailing 12-month revenue of around $1.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.25 |
|---|---|
| 52-week range | $0.21 - $12.20 |
| 50-day moving average | $0.24 |
| 200-day moving average | $1.14 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-5.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2381 from 2024-11-20
| 1 week (2024-11-15) | 5.03% |
|---|---|
| 1 month (2024-10-23) | -1.24% |
| 3 months (2024-08-22) | -37.01% |
| 6 months (2024-05-22) | -79.65% |
| 1 year (2023-11-22) | -96.80% |
|---|---|
| 2 years (2022-11-22) | -99.09% |
| 3 years (2021-11-22) | 189.8 |
| 5 years (2019-11-19) | N/A |
| Revenue TTM | $1.7 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -38.85% |
| Return on equity TTM | -85.91% |
| Profit margin | 0% |
| Book value | $1.93 |
| Market Capitalization | $3 million |
TTM: trailing 12 months
We're not expecting Scisparc to pay a dividend over the next 12 months.
You may also wish to consider:
Scisparc's shares were split on a 1:26 basis on 27 September 2023 . So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Scisparc shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Scisparc shares which in turn could have impacted Scisparc's share price.
Over the last 12 months, Scisparc's shares have ranged in value from as little as $0.206 up to $12.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scisparc's is 1.037. This would suggest that Scisparc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Scisparc's beta into context you can compare it against those of similar companies.
SciSparc Ltd. , a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.